论文部分内容阅读
目的:探讨伐昔洛韦联合咪喹莫特乳膏对预防频发性生殖器疱疹复发的疗效及安全性。方法:将2009年至2012年东莞市太平人民医院收治的102例频发性生殖器疱疹患者分为治疗组(52例)和对照组(50例)。两组均口服伐昔洛韦片450 mg,每日2次;治疗组加用咪喹莫特乳膏外用,每周3次;疗程均为3个月。观察两组患者治愈率、有效率和复发率。结果:治疗组痊愈率、总有效率略高于对照组,但差异无统计学意义(x~2=0.812,P>0.05)。治疗组总复发率(36.5%)低于对照组总复发率(82.0%),两组比较,差异有统计学意义(x~2=9.781,P<0.05)。两组治疗期间均未发生严重不良反应。结论:伐昔洛韦联合咪喹莫特乳膏比单用伐昔洛韦更能减低频发性生殖器疱疹的复发率,值得临床推广。
Objective: To investigate the efficacy and safety of valacyclovir combined with imiquimod cream in preventing recurrent genital herpes. Methods: 102 cases of frequent genital herpes admitted to Taiping People’s Hospital of Dongguan from 2009 to 2012 were divided into treatment group (52 cases) and control group (50 cases). Both groups were oral valacyclovir tablets 450 mg, 2 times a day; the treatment group with imiquimod cream applied three times a week; course of treatment were 3 months. The cure rate, effective rate and recurrence rate of the two groups were observed. Results: The cure rate and total effective rate in the treatment group were slightly higher than those in the control group, but the difference was not statistically significant (x ~ 2 = 0.812, P> 0.05). The total recurrence rate (36.5%) in the treatment group was lower than that in the control group (82.0%). There was significant difference between the two groups (x ~ 2 = 9.781, P <0.05). No severe adverse reactions occurred during the two groups. Conclusion: Valaciclovir combined with imiquimod cream more than valaciclovir alone can reduce the frequency of recurrent genital herpes recurrence, worthy of clinical promotion.